MARSHALL WACE, LLP

Position in AXSM — Axsome Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in AXSM

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$54,678,190

+$30,806,483 QoQ

Shares Held

223,386

+58.2% QoQ

Ownership

0.426%

of shares outstanding

% of Portfolio

0.07%

of 13F equity value

Holder Rank

#46

of 503 holders

Holding Since

Mar 2020

13 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,014,740,742 across 267 Biotechnology names. AXSM ranks #12 (1.8% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	543,897	$270,169,956
2	INCY	Incyte Corp	1,310,154	$148,519,056
3	RPRX	Royalty Pharma plc	2,450,669	$137,409,009
4	SYRE	Spyre Therapeutics, Inc.	991,693	$88,042,503
5	ALNY	Alnylam Pharmaceuticals, Inc.	259,799	$78,207,292
6	TVTX	Travere Therapeutics, Inc.	1,333,207	$75,739,488
7	MANE	Veradermics, Inc	585,560	$71,988,746
8	DFTX	Definium Therapeutics, Inc.	1,298,946	$61,102,419

13 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$54,678,190	223,386	+58.2%	Shares	Other	2026-08-13
2026-03-31	$23,871,707	141,236	-55.9%	Shares	Other	2026-05-15
2025-12-31	$58,548,538	320,568	-15.2%	Shares	Other	2026-02-13
2025-09-30	$45,911,013	378,024	+566.5%	Shares	Other	2025-11-13
2025-06-30	$5,920,582	56,716	-17.4%	Shares	Other	2025-08-13
2025-03-31	$8,012,014	68,696	-45.9%	Shares	Other	2025-05-15
2024-12-31	$10,753,676	127,097	+114.5%	Shares	Other	2025-02-13
2023-09-30	$4,140,842	59,248	-69.1%	Shares	Other	2023-11-14
2023-06-30	$13,761,980	191,511	+2589.4%	Shares	Other	2023-08-14
2023-03-31	$439,223	7,121	-74.0%	Shares	Other	2023-05-15
2022-06-30	$1,049,151	27,393	+17.2%	Shares	Other	2022-08-15
2021-03-31	$1,323,435	23,374	-70.6%	Shares	Sole	2021-05-17
2020-03-31	$4,674,278	79,454	—	Shares	Sole	2020-05-15
No filing history on record for this holder in this stock.